Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396794 | 0.90 | MAPK8 (0.59) | MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL7370502 | 0.89 | MAPK8 (0.62) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7372559 | 0.87 | MAPK8 (0.58) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7369625 | 0.87 | MAPK8 (0.55) | MAPK8HPGDKMT2AADRA2AADRA2B | |
| SCHEMBL7366732 | 0.87 | HPGD (0.61) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7373017 | 0.87 | MAPK8 (0.60) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7376133 | 0.86 | MAPK8 (0.57) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7399781 | 0.86 | MAPK8 (0.57) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7403963 | 0.86 | MAPK8 (0.59) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7370868 | 0.85 | MAPK8 (0.58) | MAPK8HPGDKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |